Acute Lymphocytic Leukemia Market to 2030 - Insight, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Acute Lymphocytic Leukemia (ALL): Market Insight, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the ALL, historical and forecasted epidemiology as well as the ALL market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The ALL market report provides current treatment practices, emerging drugs, ALL market share of the individual therapies, current and forecasted ALL market size from 2017 to 2030 segmented by seven major markets. The report also covers current ALL treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Leukemia is a term given to a group of cancers that develop in the blood and bone marrow. It originates in developing blood cells that have undergone a malignant change, which means they multiply in an uncontrolled manner, leaving them unformed and inoperative.

Leukemia can be either acute or chronic. In chronic leukemia, there is an accumulation of mature but abnormal white blood cells that have undergone a malignant change when developing from a blast cell. It progresses more slowly than acute leukemia and may not require treatment for a long time after it is diagnosed.

On the other hand, with acute leukemia, the diseased bone marrow produces an excessive number of abnormal blast cells, called leukemic cells. These cells accumulate in the bone marrow interfering with the production of normal blood cells. Acute leukemia develops and progresses quickly, and therefore, needs to be treated as soon as it is detected.

Typical forms of acute leukemia include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APML).

Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts. Because the bone marrow is unable to make adequate numbers of red cells, normal white cells, and platelets, people with ALL become more susceptible to anemia, recurrent infections, and to bruising and bleeding easily. The blast cells can then spill out of the bone marrow into the bloodstream and accumulate in various organs including the lymph nodes or glands, spleen, liver, and central nervous system (brain and spinal cord).

ALL is mainly classified into B-cell and T-cell ALL. ALL can occur at any age but is more common in young children (0-14 years) and it develops quickly, around 54% of ALL cases in US diagnosed among people aged &lessThan;20 years. Among children, B-cell lineage ALL constitutes approximately 88% of cases. Among adults, B-cell lineage represents around 75% of cases.

Acute Lymphocytic Leukemia Treatment

ALL is a malignant clonal disease that usually develops when a lymphoid progenitor cell turns into genetically altered through somatic changes and goes through uncontrolled proliferation. This progression of clonal expansion further leads to ALL. However, common treatment of ALL divided into distinct phases such as Induction therapy, Consolidation therapy, Maintenance therapy, and Preventive treatment to the spinal cord, among others.

  • Induction Therapy - The main purpose of the first phase of treatment is to kill most of the leukemia cells in the bone marrow and blood also to restore normal blood cell production.
  • Consolidation Therapy - Consolidation therapy is also known as post-remission therapy. The main purpose of this therapy is to completely wipe out remaining leukemia in the body, such as in the brain or spinal cord. Consolidation therapy is also known as post-remission therapy.
  • Maintenance Therapy - This is known as the third phase of treatment, which prevents leukemia cells from regrowth. However, the treatment used in this stage is often given at much lesser doses for a long period, often years.
  • Preventive treatment to the spinal cord - In this phase of therapy, a patient suffering from ALL may receive additional treatment from killing leukemia cells which are located in the central nervous system. Also, in this type of treatment phase chemotherapy drugs are often injected directly into the fluid that covers the spinal

Country-wise ALL Epidemiology

  • Estimates show that the highest cases of ALL in the 7MM were in the United States, followed by Germany, Japan, France, the United Kingdom, Italy, and Spain in 2017.
  • In the United States, the total number of incident cases of ALL was 5,816 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
  • In the year 2017, the total incident cases of ALL were 3,652 cases in EU-5 which are expected to grow during the study period, i.e., 2017-2030.
  • In Japan, the total number of incident cases of ALL was 872 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the ALL market.
  • To understand the future market competition in the ALL market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for ALL in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for ALL market.
  • To understand the future market competition in the ALL market.

Companies Mentioned

  • AbbVie
  • Allogene
  • Amgen
  • Autolus Limited
  • Bellicum Pharmaceuticals
  • BioLine Rx
  • Bristol-Myers Squibb
  • Fate Therapeutics
  • Gamida Cell Ltd.
  • Gilead Sciences
  • Incyte Corporation
  • Janssen Research & Development
  • Jazz Pharmaceuticals
  • MiltenyiBiotec B.V. & Co. KG
  • Novartis Pharmaceuticals
  • Otsuka Pharmaceuticals
  • Pfizer
  • Pharmacyclics (an AbbVie Company)
  • Porton Biopharma Limited
  • Precision BioSciences
  • Roche
  • Sanofi
  • Servier Pharmaceuticals
  • Takara Bio
  • Takeda (Ariad Pharmaceuticals)
  • TCR2 Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/cejzsq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900